Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants

Phase 1 Completed 14 enrolled Agomab Therapeutics NV

NaSingle-groupOpen-labelBasic science

Summary

This is a single-center, open-label, fixed-sequence, Phase 1 study in healthy adult participants to evaluate the effect of AGMB-129 on the PK of a single dose of MDZ in healthy participants. A total of 14 participants will be enrolled and will receive study intervention in a fixed-sequence scheme. All IP will be administered orally and in fed conditions. The total duration of involvement for each participant, screening through follow-up, will be approximately 6 weeks.

Timeline

Start: 2023-08-09
Primary completion: 2023-09-06
Completion: 2023-09-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AGMB-129	Unknown	—	Oral
Subject	MDZ	Unknown	—	Oral

Indications

No indication recorded.